Jyoti D. Patel, MD

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.

Experts on non–small cell lung cancer reflect on clinical trial data to weigh treatment options for patients with EGFR-mutated non–small cell lung cancer.

Jyoti D. Patel, MD, and Rajat Thawani, MBBS, tackle the question of whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable non–small cell lung cancer.

Robert B. Cameron, MD, PhD, offers insights on a patient with KRAS G12C non–small cell lung cancer.

Focusing on PD-L1-low NSCLC, Faith Abodunrin, MD, discusses the decision to rechallenge with immunotherapy.

Jyoti Patel, MD, presents the case of a patient with EGFR-mutated non–small cell lung cancer requiring treatment following osimertinib.

Initiating a conversation on patient cases, Divya Gupta, MD, presents the profile of a 76-year-old woman with ROS1+ metastatic non–small cell lung cancer.

Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.

Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.

Focusing on the CROWN study, Faith Abodunrin, MD, discusses the role of lorlatinib in the treatment of patients with non–small cell lung cancer.

Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.

Joshua K. Sabari, MD, introduces a Face-Off program in which Northwestern University and the University of Chicago will present data and discuss treatment practices in non–small cell lung cancer.

Lung cancer remains the leading cause of cancer death in Americanmen and women. Non–small-cell lung cancer (NSCLC) accountsfor 85% of these cases. Although surgery is the best curative approachfor resectable NSCLC, long-term survival for patients with operabledisease remains poor. More than half of patients who initially presentwith stage I to IIIA disease experience relapse of metastatic disease.Postoperative adjuvant therapy has been evaluated in several randomizedtrials, and provides a survival benefit. It appears reasonable tolook to induction chemotherapy, or preoperative chemotherapy, to providea similar improvement in survival with early treatment ofmicrometastatic disease. Multiple trials of induction therapy have beencarried out with encouraging results. The use of various induction regimenswith chemotherapy alone or chemotherapy combined with radiotherapyfor stage IIIA NSCLC is under investigation. Randomized trialsare under way to better define the role of induction therapy in themultimodality treatment of NSCLC.